Author:
Hu Xingsheng,Zhang Li,Shi Yuankai,Zhou Caicun,Liu Xiaoqing,Wang Dong,Song Yong,Li Qiang,Feng Jifeng,Qin Shukui,Xv Nong,Zhou Jianying,Zhang Li,Hu Chunhong,Zhang Shucai,Luo Rongcheng,Wang Jie,Tan Fenlai,Wang Yinxiang,Ding Lieming,Sun Yan
Publisher
Public Library of Science (PLoS)
Reference26 articles.
1. Cancer statistics, 2012;R Siegel;CA Cancer J Clin,2012
2. Lung cancer;RS Herbst;N Engl J Med,2008
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;R Rosell;Lancet Oncol,2012
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study;C Zhou;Lancet Oncol,2011
5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;TS Mok;N Engl J Med,2009
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献